APA (7th ed.) Citation

Berkelmans, G. F. N., Greving, J. P., Graaf, Y. v. d., Visseren, F. L. J., & Dorresteijn, J. A. N. (2020). Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective? BMC.

Chicago Style (17th ed.) Citation

Berkelmans, Gijs F. N., Jacoba P. Greving, Yolanda van der Graaf, Frank L. J. Visseren, and Jannick A. N. Dorresteijn. Would Treatment Decisions About Secondary Prevention of CVD Based on Estimated Lifetime Benefit Rather than 10-year Risk Reduction Be Cost-effective? BMC, 2020.

MLA (9th ed.) Citation

Berkelmans, Gijs F. N., et al. Would Treatment Decisions About Secondary Prevention of CVD Based on Estimated Lifetime Benefit Rather than 10-year Risk Reduction Be Cost-effective? BMC, 2020.